Similar articles for PMID: 16301688

Year	Number of Results
1999	1
2000	1
2001	1
2002	5
2003	7
2004	13
2005	9
2006	9
2007	9
2008	12
2009	13
2010	8
2011	4
2012	3
2013	1
2014	2
2015	1
2016	2
2019	1
2021	1
2024	0

1

Clinical practice guidelines and conflict of interest.

[No authors listed] [No authors listed] CMAJ. 2005 Nov 22;173(11):1297, 1299. doi: 10.1503/cmaj.051423. CMAJ. 2005. PMID: 16301688 Free PMC article. No abstract available.

2

Long-acting insulin analogs versus human insulins.

Garg SK, Naik RG. Garg SK, et al. Diabetes Technol Ther. 2008 Oct;10(5):331-2. doi: 10.1089/dia.2008.0071. Diabetes Technol Ther. 2008. PMID: 18715208 No abstract available.

3

Insulin glargine: a new basal insulin analogue.

Younis N, Soran H, Bowen-Jones D. Younis N, et al. QJM. 2002 Nov;95(11):757-61. doi: 10.1093/qjmed/95.11.757. QJM. 2002. PMID: 12391389 Review. No abstract available.

4

Insulin glargine clinical trials.

White JR Jr. White JR Jr. Clin Ther. 2004 Jul;26(7):1179-81; discussion 1182-3. doi: 10.1016/s0149-2918(04)90190-7. Clin Ther. 2004. PMID: 15336483 Review. No abstract available.

5

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

Grima DT, Thompson MF, Sauriol L. Grima DT, et al. Pharmacoeconomics. 2007;25(3):253-66. doi: 10.2165/00019053-200725030-00007. Pharmacoeconomics. 2007. PMID: 17335310

6

New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?

Standl E, Owen DR. Standl E, et al. Diabetes Care. 2016 Aug;39 Suppl 2:S172-9. doi: 10.2337/dcS15-3011. Diabetes Care. 2016. PMID: 27440830 No abstract available.

7

Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.

Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J. Guillermin AL, et al. J Med Econ. 2011;14(2):207-16. doi: 10.3111/13696998.2011.561390. Epub 2011 Mar 2. J Med Econ. 2011. PMID: 21361858 Free article.

8

Insulin Glargine: a review 8 years after its introduction.

Goykhman S, Drincic A, Desmangles JC, Rendell M. Goykhman S, et al. Expert Opin Pharmacother. 2009 Mar;10(4):705-18. doi: 10.1517/14656560902775677. Expert Opin Pharmacother. 2009. PMID: 19284367 Review.

9

Optimizing glycemic control with insulin glargine.

Williams JB. Williams JB. Diabetes Technol Ther. 2003;5(3):471-3. doi: 10.1089/152091503765692009. Diabetes Technol Ther. 2003. PMID: 12828834 No abstract available.

10

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME. Tunis SL, et al. Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000. Appl Health Econ Health Policy. 2010. PMID: 20578781 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year